Sugi Predict

Sugi Predict / Compounds / SCHEMBL177666

SCHEMBL177666

SCHEMBL177666

CCC(=O)NN1CN([C@@H]2O[C@H](CO)C(O)C2O)c2ncnc(N)c21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSPA8 P11142 3/20 0.44
▸ MAPK1 P28482 3/20 0.43
▸ HIF1A Q16665 3/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ STAT6 P42226 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ HSPA5 P11021 2/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ DOT1L Q8TEK3 2/20 0.43
▸ DPP4 P27487 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ SLC28A1 O00337 1/20 0.43
▸ MAP3K7 O43318 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1976100 0.90 HSPA8 (0.46) HSPA8MAPK1HIF1ATDP1STAT6
SCHEMBL7744270 0.89 MAPK1 (0.40) HSPA8MAPK1HIF1ATDP1STAT6
SCHEMBL7617960 0.88 ADORA3 (0.43) HSPA8MAPK1HIF1ATDP1STAT6
SCHEMBL6636043 0.87 MAPK1 (0.38) MAPK1HIF1ATDP1STAT6CYP1A2
SCHEMBL258936 0.85 LMNA (0.36) HSPA8ALDH1A1TP53HTTHSPA5
SCHEMBL7746161 0.84 HSPA8 (0.42) HSPA8MAPK1HIF1ASTAT6HSPA5
SCHEMBL7161653 0.83 TSHR (0.51) HIF1ATDP1TP53HTTRXFP1
SCHEMBL1320879 0.81 ADORA3 (0.51) HSPA8TDP1TP53SLC28A2ADORA3
SCHEMBL830795 0.80 MAPK1 (0.50) HSPA8MAPK1HIF1ATDP1STAT6
SCHEMBL830796 0.80 MAPK1 (0.50) HSPA8MAPK1HIF1ATDP1STAT6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 892 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 — — EP claimed
US-20250262274-A1 Designed Biosensors for Enhanced T Cell Therapy ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) 2025-08-21 — — US claimed
EP-4526335-A1 DESIGNED BIOSENSORS FOR ENHANCED T CELL THERAPY Centre Hospitalier Universitaire Vaudois (CH) 2025-03-26 — — EP claimed
US-20250090673-A1 CONJUGATE FOR TARGETING CENTRAL NERVOUS SYSTEM SUNTEC MEDICAL INC (US) 2025-03-20 — — US claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 — — WO claimed
WO-2023222829-A1 DESIGNED BIOSENSORS FOR ENHANCED T CELL THERAPY CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (CH) 2023-11-23 — — WO claimed
WO-2023196235-A1 METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES GLAZIER ALAN NEIL (US) 2023-10-12 — — WO claimed
US-20230310471-A1 METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES GLAZIER ALAN NEIL (US) 2023-10-05 — — US claimed
US-11771678-B2 Therapeutic agent for neuropathy in organic acidemia of which mechanism relies on increase in cAMP NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) 2023-10-03 — — US claimed
CN-116200330-A Method for down-regulating MAPK8 expression to induce reprogramming of cells into mammary epithelial cells 广西壮族自治区人民医院 2023-06-02 — — CN claimed
US-20010009907-A1 Compositions and methods for preventing restenosis following revascularization procedures DISCOVERY THERAPEUTICS, INC. 2001-07-26 — — US claimed
EP-1014995-A1 COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES Discovery Therapeutics, Inc. (US) 2000-07-05 — — EP claimed
US-5942497-A Purine compound and catecholamine compound containing compositions and methods for administration ADENOCOMP, LLC 1999-08-24 — — US claimed
EP-0735888-A4 PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION FUKUNAGA ATSUO F (US) 1999-05-12 — — EP claimed
WO-1998057651-A1 COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSIS FOLLOWING REVASCULARIZATION PROCEDURES DISCOVERY THERAPEUTICS, INC. (US) 1998-12-23 — — WO claimed
US-5679650-A SIDE EFFECT REDUCTION ADENOCOMP, LLC 1997-10-21 — — US claimed
US-5573772-A PROTECTING AN ORGAN HAVING A3 ADENOSINE RECEPTORS BY ADMINISTERING A3 ADENOSINE RECEPTOR AGONIST BY ORAL, INTRAVENOUS OR PERFUSION TECHNIQUE GENSIA, INC. (US) 1996-11-12 — — US claimed
EP-0735888-A1 PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION FUKUNAGA, Atsuo F. (US) 1996-10-09 — — EP claimed
US-5424297-A Adenosine dextran conjugates UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) 1995-06-13 — — US claimed
WO-1995014478-A1 PURINE COMPOSITIONS AND METHODS FOR ADMINISTRATION FUKUNAGA ATSUO F (US) 1995-06-01 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250090673-A1 CONJUGATE FOR TARGETING CENTRAL NERVOUS SYSTEM PYGB, PMP22, GMFG HSPA8 1014/4885MAPK1 2459/4885HIF1A 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.